当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.

Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.

Abstract：

:Patients with normal-karyotype acute myelogenous leukemia (NKAML) may have undetected genetic abnormalities that could affect prognosis. Screening for known AML-specific genetic abnormalities using the reverse transcription polymerase chain reaction (RT-PCR) may help in arriving at a more definitive prognosis. To test this hypothesis, 104 patients without translocation (8;21) and inversion(16), as shown by standard cytogenetic (SC) analysis, were screened for these two genetic abnormalities using RT-PCR. Western blot analysis for the AML1/ETO fusion protein and fluorescent in situ hybridization (FISH) analysis for t(8;21) were performed in patients for whom we had samples. The characteristics and outcome after high-dose cytarabine containing treatments in five patients with t(8;21) shown by RT-PCR alone were then compared to 21 patients with t(8;21) detected using SC analysis. Eight of the 104 patients had masked t(8;21) and none had masked inv(16), as shown by RT-PCR. Five of 54 patients with NKAML had a detectable AML1/ETO fusion RNA transcript. Western blot analysis showed the AML1/ETO fusion protein in four of the seven patients for whom we had samples among the eight with masked t(8;21) shown by RT-PCR. All patients with t(8;21) shown by RT-PCR had negative FISH results. Ninety percent (n=19) of the patients with t(8;21) shown by SC analysis and 40% (n= 2) of the patients with t(8;21) shown by RT-PCR alone achieved a complete remission (P value 0.03). These data suggest that the outcome of NKAML patients with t(8;21) shown by RT-PCR is not equivalent to patients with t(8;21) by SC studies.

journal_name

Leukemia

journal_title

Leukemia

authors

Sarriera JE,Albitar M,Estrov Z,Gidel C,Aboul-Nasr R,Manshouri T,Kornblau S,Chang KS,Kantarjian H,Estey E

doi

10.1038/sj.leu.2401951

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

57-61

issue

1

eissn

0887-6924

issn

1476-5551

journal_volume

15

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha.

    abstract：:Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403610

    authors： Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

    更新日期：2005-02-01 00:00:00

  • Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia.

    abstract：:Allelic losses on chromosome 12p12-13 are associated with childhood acute lymphoblastic leukemia (ALL) and several solid neoplasias, suggesting the presence of a tumor suppressor locus. The recent construction of a transcription map of this locus has enabled the identification of eight genes, of which five were previo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403441

    authors： Montpetit A,Larose J,Boily G,Langlois S,Trudel N,Sinnett D

    更新日期：2004-09-01 00:00:00

  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract：:Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.78

    authors： Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期：2014-09-01 00:00:00

  • Natural killer-cell malignancies: diagnosis and treatment.

    abstract：:Natural killer (NK)-cell malignancies are uncommon diseases. Previously known as polymorphic reticulosis or angiocentric T-cell lymphomas, they are classified by the World Health Organization as NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia. They are prevalent in Asia and South America, but exceptiona...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2403955

    authors： Kwong YL

    更新日期：2005-12-01 00:00:00

  • Is the mdr 1 gene relevant in chronic lymphocytic leukemia?

    abstract：:Chronic lymphocytic leukemia (CLL) is a progressive disease in which chemotherapy may result in temporary suppression of the peripheral blood lymphocyte count, but cure is not usually possible. Drug resistance mechanisms and the multidrug resistant (MDR) phenotype may be relevant to the therapeutic response. We have s...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Holmes JA,Jacobs A,Carter G,Whittaker JA,Bentley DP,Padua RA

    更新日期：1990-03-01 00:00:00

  • Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

    abstract：:We have developed a method to quantify topoisomerase (topo) II activities in partially purified nuclear extracts from human leukemia cells. By virtue of their different pH optima in the reaction buffer, two different topo II activities were found with activity optima at pH 7.9 and at pH 8.9 under high stringency condi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gieseler F,Glasmacher A,Kämpfe D,Wandt H,Nuessler V,Valsamas S,Kunze J,Wilms K

    更新日期：1996-07-01 00:00:00

  • Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia.

    abstract：:We used fluorescence in situ hybridization (FISH) to metaphase chromosomes with BCR and ABL cosmid probes in conjunction with the polymerase chain reaction (PCR) to study the mechanism by which the ABL proto-oncogene is inserted into a morphologically normal chromosome 22 in patients with Ph-negative chronic myeloid l...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lazaridou A,Chase A,Melo J,Garicochea B,Diamond J,Goldman J

    更新日期：1994-03-01 00:00:00

  • Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.

    abstract：:Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0936-4

    authors： Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

    更新日期：2020-10-01 00:00:00

  • Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.

    abstract：:The transcription factor CCAAT/enhancer binding protein a (C/EBPalpha) is important in the regulation of granulopoiesis and is disrupted in human acute myeloid leukemia. In the present study, we sought to identify novel C/EBPalpha interacting proteins in vivo through immunoprecipitation using mass spectrometry-based p...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404438

    authors： Zada AA,Pulikkan JA,Bararia D,Geletu M,Trivedi AK,Balkhi MY,Hiddemann WD,Tenen DG,Behre HM,Behre G

    更新日期：2006-12-01 00:00:00

  • Current recommendations for positive controls in RT-PCR assays.

    abstract：:The choice of adequate controls for reverse transcriptase (RT-) PCR analysis has been the focus of a debate pursued in Leukemia over the past 3 years. Twenty-six authors from 15 different centers contributed to the Debate, and the points presented have been carefully evaluated. This survey reviews the issues discussed...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2402133

    authors： Lion T

    更新日期：2001-07-01 00:00:00

  • Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma.

    abstract：:Osteolysis resulting in extensive bone damage is a major clinical manifestation of patients with multiple myeloma (MM). The mechanisms of bone resorption in MM are incompletely understood. The final pathway is the generation of activated osteoclasts within bone marrow (BM) microenvironment. To investigate the mechanis...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gregoretti MG,Bergui L,Aragno M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期：1995-08-01 00:00:00

  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

    abstract：:Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41375-020-0718-z

    authors： Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

    更新日期：2020-07-01 00:00:00

  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract：:RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41375-019-0603-9

    authors： Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期：2020-03-01 00:00:00

  • Efficient gene transfer in CLL by mRNA electroporation.

    abstract：:Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2405007

    authors： Van Bockstaele F,Pede V,Naessens E,Van Coppernolle S,Van Tendeloo V,Verhasselt B,Philippé J

    更新日期：2008-02-01 00:00:00

  • Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.

    abstract：:During the 15 year period 1975-1989, 74 cases of chronic myeloproliferative disorder (CMPD) were cytogenetically analyzed in our department. Thirty patients had polycythemia vera (PV), 23 had idiopathic myelofibrosis (MFS), 15 had idiopathic thrombocythemia (IT), and six had unclassifiable CMPD (UCMPD). The overall fr...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Mertens F,Johansson B,Heim S,Kristoffersson U,Mitelman F

    更新日期：1991-03-01 00:00:00

  • Biologic response modifiers in acute lymphoblastic leukemia.

    abstract：:Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Gribben JG,Cardoso AA,Schultze JL,Nadler LM

    更新日期：1997-05-01 00:00:00

  • The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

    abstract：:The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.233

    authors： Zhan H,Lin CHS,Segal Y,Kaushansky K

    更新日期：2018-02-01 00:00:00

  • SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

    abstract：:Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.256

    authors： Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

    更新日期：2014-04-01 00:00:00

  • Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

    abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404734

    authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

    更新日期：2007-07-01 00:00:00

  • Integrin distribution and cytoskeleton organization in normal and malignant monocytes.

    abstract：:In this work we have mapped by double-label immunofluorescence the cellular distribution of integrins and their relationship with cytoskeletal proteins in normal and malignant monocytes. In normal monocytes, CD18 and CD11c are concentrated at specific adhesion sites, named podosomes, together with actin, vinculin, and...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gaidano G,Bergui L,Schena M,Gaboli M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期：1990-10-01 00:00:00

  • The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.

    abstract：:Retinoic acid receptor (RA) heterodimer (RAR/RXR) activities have been shown to be repressed by transcriptional co-repressor, SMRT/N-CoR, in the absence of the ligand while upon all-trans retionic acid (ATRA) treatment, SMRT/N-CoR is dissociated from RARalpha leading to gene expression by the recruitment of transcript...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401643

    authors： So CW,Dong S,So CK,Cheng GX,Huang QH,Chen SJ,Chan LC

    更新日期：2000-01-01 00:00:00

  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract：:P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.153

    authors： Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期：2015-12-01 00:00:00

  • Interstitial telomere repeats in translocations of hematopoietic disorders.

    abstract：:Cytogenetic and fluorescence in situ hybridization studies have shown the presence of telomeric repeats in translocation present in three patients with hematopoietic malignancies. One had jumping translocations, involving 1q12 and 2q, 16p, and 19q. These sequences were detected by FISH only in derivative chromosomes t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401876

    authors： Busson Le Coniat M,Brizard F,Smadja NV,Maarek O,Der Sarkissian H,Berger R

    更新日期：2000-09-01 00:00:00

  • Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.

    abstract：:Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia unspecified (one case) or s-myelodysplastic syndrome (five cases) following treatment for a primary malignancy. B...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401021

    authors： Secker-Walker LM,Moorman AV,Bain BJ,Mehta AB

    更新日期：1998-05-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract：:We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2405014

    authors： de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期：2008-02-01 00:00:00

  • Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia.

    abstract：:A 23-year-old male found to have Philadelphia chromosome-positive chronic myeloid leukemia (CML) in May 1987 suffered a myeloid blastic transformation in April 1993. A second chronic phase was achieved after treatment with daunorubicin and cytosine arabinoside and the patient then underwent autologous bone marrow tran...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Spencer A,Vulliamy T,Chase A,Goldman JM

    更新日期：1995-12-01 00:00:00

  • Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.

    abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400732

    authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

    更新日期：1997-08-01 00:00:00

  • Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

    abstract：:Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.118

    authors： Modlich U,Schambach A,Brugman MH,Wicke DC,Knoess S,Li Z,Maetzig T,Rudolph C,Schlegelberger B,Baum C

    更新日期：2008-08-01 00:00:00

  • AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

    abstract：:The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.33

    authors： Stankiewicz MJ,Crispino JD

    更新日期：2013-06-01 00:00:00

  • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

    abstract：:Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated t...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2008.174

    authors： Breitkreutz I,Raab MS,Vallet S,Hideshima T,Raje N,Mitsiades C,Chauhan D,Okawa Y,Munshi NC,Richardson PG,Anderson KC

    更新日期：2008-10-01 00:00:00